Can be steroid-refractory (PMID 30176946, 30301729, 30837232)), requiring additional immunosuppression/modulation with e.g. IVIG, infliximab, or MMF. The development of ICPI-related ILD may negatively impact the outcome in lung cancer patients

Last update : 10/03/2019